Literature DB >> 7635574

The epithelial/carcinoma antigen EGP-1, recognized by monoclonal antibody RS7-3G11, is phosphorylated on serine 303.

A Basu1, D M Goldenberg, R Stein.   

Abstract

RS7-3G11 is a murine monoclonal antibody (MAb) raised against human non-small-cell lung carcinoma, and is under clinical evaluation. The epithelial/carcinoma antigen EGP-1, defined by RS7-3G11, was isolated and purified to homogeneity from a cervical carcinoma cell line, ME180. EGP-1 is a glycoprotein with an average molecular mass of 47.8 kDa. Metabolic labeling of the antigen with 32P-orthophosphate and subsequent immunoprecipitation with RS7-3G11 showed that it is a phosphoprotein. Phosphoamino acid analysis of the in vivo phosphorylated EGP-1 revealed that the phosphorylation is on serine. In vitro analysis with purified antigen demonstrated that protein kinase C, and not protein kinase A, is involved in phosphorylating the antigen in vitro. In vitro analysis indicated a stoichiometry of phosphorylation of 0.54 mole of phosphate per mole of EGP-1. Phosphoamino acid analysis and phosphopeptide mapping of the antigen phosphorylated in vitro by protein kinase C showed that phosphorylation occurred on a serine residue, specifically on serine 303, located in the cytoplasmic domain of EGP-1. Treatment of ME180 cells with phorbol ester increased the phosphorylation of EGP-1. The biological function of EGP-1 remains to be elucidated. In this report we elucidate an involvement of protein kinase C in phosphorylating EGP-1, which may signify a role for this antigen in signal transduction across the cell membrane.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7635574     DOI: 10.1002/ijc.2910620419

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  20 in total

Review 1.  The emerging role of antibody-drug conjugates in urothelial carcinoma.

Authors:  Michael Lattanzi; Jonathan E Rosenberg
Journal:  Expert Rev Anticancer Ther       Date:  2020-07-21       Impact factor: 4.512

2.  Pretargeted immunoPET of prostate cancer with an anti-TROP-2 x anti-HSG bispecific antibody in mice with PC3 xenografts.

Authors:  Catharina M van Rij; Cathelijne Frielink; David M Goldenberg; Robert M Sharkey; Gerben M Franssen; Susanne Lütje; William J McBride; Wim J G Oyen; Otto C Boerman
Journal:  Mol Imaging Biol       Date:  2015-02       Impact factor: 3.488

3.  Trophoblast cell surface antigen 2 (Trop-2) phosphorylation by protein kinase C α/δ (PKCα/δ) enhances cell motility.

Authors:  Yugo Mori; Kaoru Akita; Kazuki Ojima; Shungo Iwamoto; Tomoko Yamashita; Eiichi Morii; Hiroshi Nakada
Journal:  J Biol Chem       Date:  2019-06-07       Impact factor: 5.157

4.  Regulated proteolysis of Trop2 drives epithelial hyperplasia and stem cell self-renewal via β-catenin signaling.

Authors:  Tanya Stoyanova; Andrew S Goldstein; Houjian Cai; Justin M Drake; Jiaoti Huang; Owen N Witte
Journal:  Genes Dev       Date:  2012-10-15       Impact factor: 11.361

5.  Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer.

Authors:  Aditya Bardia; Ingrid A Mayer; Jennifer R Diamond; Rebecca L Moroose; Steven J Isakoff; Alexander N Starodub; Nikita C Shah; Joyce O'Shaughnessy; Kevin Kalinsky; Michael Guarino; Vandana Abramson; Dejan Juric; Sara M Tolaney; Jordan Berlin; Wells A Messersmith; Allyson J Ocean; William A Wegener; Pius Maliakal; Robert M Sharkey; Serengulam V Govindan; David M Goldenberg; Linda T Vahdat
Journal:  J Clin Oncol       Date:  2017-03-14       Impact factor: 44.544

6.  Pretargeted immuno-PET and radioimmunotherapy of prostate cancer with an anti-TROP-2 x anti-HSG bispecific antibody.

Authors:  Catharina M van Rij; Susanne Lütje; Cathelijne Frielink; Robert M Sharkey; David M Goldenberg; Gerben M Franssen; William J McBride; Edmund A Rossi; Wim J G Oyen; Otto C Boerman
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-05-15       Impact factor: 9.236

7.  Pretargeted Radioimmunotherapy of Prostate Cancer with an Anti-TROP-2×Anti-HSG Bispecific Antibody and a (177)Lu-Labeled Peptide.

Authors:  Catharina M van Rij; Cathelijne Frielink; David M Goldenberg; Robert M Sharkey; Susanne Lütje; William J McBride; Wim J G Oyen; Otto C Boerman
Journal:  Cancer Biother Radiopharm       Date:  2014-09-16       Impact factor: 3.099

8.  Trop2 expression contributes to tumor pathogenesis by activating the ERK MAPK pathway.

Authors:  Rafael Cubas; Sheng Zhang; Min Li; Changyi Chen; Qizhi Yao
Journal:  Mol Cancer       Date:  2010-09-21       Impact factor: 27.401

9.  Trop-2 protein overexpression is an independent marker for predicting disease recurrence in endometrioid endometrial carcinoma.

Authors:  Eliana Bignotti; Laura Zanotti; Stefano Calza; Marcella Falchetti; Silvia Lonardi; Antonella Ravaggi; Chiara Romani; Paola Todeschini; Elisabetta Bandiera; Renata A Tassi; Fabio Facchetti; Enrico Sartori; Sergio Pecorelli; Dana M Roque; Alessandro D Santin
Journal:  BMC Clin Pathol       Date:  2012-11-14

10.  High expression of TROP2 correlates with poor prognosis in pancreatic cancer.

Authors:  D Fong; P Moser; C Krammel; J M Gostner; R Margreiter; M Mitterer; G Gastl; G Spizzo
Journal:  Br J Cancer       Date:  2008-09-23       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.